Biocon's Bio-Similars: A $30 Billion Opportunity

Kiran Mazumdar Shaw, CMD at Biocon says the combined market size for the four bio-similars in Biocon's portfolio is $30 billion but only investors and analysts abroad seem to recognize the value and opportunity.

Related Videos